Value through Innovation27 August 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 next
22.09.2011

New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis

- For NON-U.S Health Media Only
21.09.2011

Viramune® (nevirapine) prolonged-release once-daily formulation for the treatment of HIV-1 infection receives approval in the EU

- For non-US healthcare media
21.09.2011

Boehringer Ingelheim enrols first patient in Phase III program for new once-daily fixed-dose combination of tiotropium plus olodaterol in COPD

- For Media outside the U.S. and Canada
16.09.2011

New data for once-daily linagliptin show durable efficacy over two years

- For Medical Media outside the US and UK only.
13.09.2011

Boehringer Ingelheim and EFSD collaborate to support diabetes research in Europe

- For NON-UK and NON-US / Medical Media only.
07.09.2011

Boehringer Ingelheim wins Frost & Sullivan Award for Biopharmaceutical Contract Manufacturing

29.08.2011

€1 million awarded to winning projects which aim to prevent atrial fibrillation-related stroke

- For non-UK and non-US media
29.08.2011

Boehringer Ingelheim Broadens its Breast Cancer Trial Programme for Afatinib*

- FOR NON-US MEDIA ONLY
28.08.2011

Pradaxa® (dabigatran etexilate, 150mg bid) shows significant reduction in the risk of stroke over warfarin in patients with atrial fibrillation taking antiplatelet or other concomitant therapies

- For NON-US and NON-UK Healthcare Media Only
26.08.2011

Pradaxa® (dabigatran etexilate) revolutionizes stroke prevention in atrial fibrillation

- For NON-US and NON-UK Healthcare Media Only
25.08.2011

Trajenta® (linagliptin) receives approval for the treatment of type 2 diabetes in Europe

- EX US and UK / Medical Media Only.
10.08.2011

Boehringer Ingelheim licenses ProBioGen's novel GlymaxX® technology

09.08.2011

Positive first half-year 2011 for Boehringer Ingelheim – new growth from innovative medicines /Pradaxa approved in Europe

04.08.2011

Breakthrough therapy PRADAXA® (dabigatran etexilate) first drug in 50 years to gain approval for stroke prevention in atrial fibrillation in EU

- For NON-US and NON-UK Healthcare Media Only
04.08.2011

First novel blood thinner in 50 years for the prevention of strokes caused by common heart rhythm disorder, approved in EU

- For NON-US and NON-UK Consumer Media Only
27.07.2011

Viramune® (nevirapine) prolonged-release once-daily formulation for the treatment of HIV-1 infection receives CHMP recommendation for approval

- For non-US healthcare media
12.07.2011

Stroke prevention: "It is time to act"

06.07.2011

Boehringer Ingelheim and Ashoka’s Changemakers
Launch "Making More Health" Competition

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 next